Table 3.
Differences in G-CSF levels by COPD disease severity after stimulation of whole blood by PAMPs
| PAMP | COPD severity
|
P-value* | |||
|---|---|---|---|---|---|
| FEV1 <50 (N=16)
|
FEV1 50–80 (N=12)
|
||||
| Median | IQR | Median | IQR | ||
| Media | 1.5 | (0.5–4.7) | 1.5 | (0.5–3.5) | 0.7 |
| Pam3Cys (10 ng/mL) | 9.0 | (4.6–18.5) | 16.9 | (5.4–37.7) | 0.2 |
| Pam3Cys (100 ng/mL) | 16.4 | (5.4–25.6) | 28.1 | (11.8–49.0) | 0.08 |
| Zymosan (10 μg/mL) | 6.5 | (1.1–10.6) | 8.3 | (5.5–16.1) | 0.1 |
| Zymosan (100 μg/mL) | 68.0 | (38.2–93.5) | 134.8 | (67.0–174.7) | 0.02 |
| FSL-1 (10 ng/mL) | 1.4 | (0.5–4.8) | 4.6 | (1.9–5.7) | 0.1 |
| FSL-1 (100 ng/mL) | 3.3 | (0.5–6.2) | 8.1 | (4.3–12.9) | 0.005 |
| O111:B4 (0.1 ng/mL) | 2.7 | (0.5–4.6) | 2.5 | (0.8–10.3) | 0.7 |
| O111:B4 (1 ng/mL) | 13.1 | (6.4–71.8) | 34.7 | (24.1–54.0) | 0.1 |
| O111:B4 (10 ng/mL) | 22.2 | (17.6–101.4) | 74.1 | (60.7–149.7) | 0.04 |
| Re595UP (0.01 ng/mL) | 6.7 | (1.1–12.4) | 14.3 | (5.8–18.8) | 0.09 |
| Re595UP (0.1 ng/mL) | 77.1 | (48.9–107.3) | 130.3 | (86.9–198.4) | 0.04 |
| Re595UP (1 ng/mL) | 216.9 | (176.9–411.4) | 332.0 | (227.3–492.5) | 0.1 |
| Flagellin (100 ng/mL) | 1.6 | (0.5–3.4) | 1.7 | (0.5–3.0) | 0.9 |
| R848 (0.1 μM) | 1.2 | (0.5–3.9) | 1.5 | (0.5–2.7) | 0.96 |
| R848 (1 μM) | 20.8 | (13.0–35.3) | 33.2 | (16.5–54.1) | 0.3 |
Note:
*
Wilcoxon rank sum test (Mann–Whitney).
Abbreviations: PAMP, pathogen-associated molecular pattern; IQR, inter-quartile range.